tiprankstipranks
Advertisement
Advertisement

IBRX Stock Latest News

ImmunityBio reports preliminary Q1 net product revenue $44.2M
The FlyImmunityBio reports preliminary Q1 net product revenue $44.2M
1d ago
IBRX
ImmunityBio Addresses FDA Warning on ANKTIVA Promotion
PremiumCompany Announcements
ImmunityBio Addresses FDA Warning on ANKTIVA Promotion
4d ago
8K
IBRX
ImmunityBio addresses FDA correspondence, reaffirms commitment to ad compliance
PremiumThe Fly
ImmunityBio addresses FDA correspondence, reaffirms commitment to ad compliance
4d ago
IBRX
ImmunityBio, Keysight, Rubrik, AFLAC, Moody’s Insider Shake-Up
PremiumWeekend Updates
ImmunityBio, Keysight, Rubrik, AFLAC, Moody’s Insider Shake-Up
6d ago
AFL
MCO
ImmunityBio Bolsters Balance Sheet With New Financing Moves
PremiumCompany Announcements
ImmunityBio Bolsters Balance Sheet With New Financing Moves
10d ago
8K
IBRX
ImmunityBio announces $100M of financing transactions
PremiumThe FlyImmunityBio announces $100M of financing transactions
10d ago
IBRX
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Soon-Shiong Allegedly Overstated ANKTIVA Efficacy: Levi & Korsinsky
Premium
Class Action
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Soon-Shiong Allegedly Overstated ANKTIVA Efficacy: Levi & Korsinsky
11d ago
IBRX
ImmunityBio Faces Securities Lawsuit Over Alleged Misleading Statements About Cancer Drug Anktiva
Premium
Class Action
ImmunityBio Faces Securities Lawsuit Over Alleged Misleading Statements About Cancer Drug Anktiva
11d ago
IBRX
ImmunityBio announces IDMC says QUILT-2.005 adequately powered
PremiumThe Fly
ImmunityBio announces IDMC says QUILT-2.005 adequately powered
15d ago
IBRX
Mixed options sentiment in ImmunityBio with shares up 6.88%
PremiumThe Fly
Mixed options sentiment in ImmunityBio with shares up 6.88%
16d ago
IBRX
“FDA Warning” on Cancer Drug Sends ImmunityBio Stock (IBRX) Tumbling over 26%
PremiumMarket News
“FDA Warning” on Cancer Drug Sends ImmunityBio Stock (IBRX) Tumbling over 26%
17d ago
IBRX
ImmunityBio’s FDA warning letter doesn’t change fundamentals, says BTIG
PremiumThe Fly
ImmunityBio’s FDA warning letter doesn’t change fundamentals, says BTIG
17d ago
IBRX
ImmunityBio falls -26.4%
PremiumThe FlyImmunityBio falls -26.4%
17d ago
IBRX
Midday Fly By: Estee Lauder in deal talks with Puig, Smithfield reports Q4 beat
Premium
The Fly
Midday Fly By: Estee Lauder in deal talks with Puig, Smithfield reports Q4 beat
17d ago
EL
RL
Option traders moderately bearish in ImmunityBio with shares down 22.61%
Premium
The Fly
Option traders moderately bearish in ImmunityBio with shares down 22.61%
17d ago
IBRX
ImmunityBio falls -23.0%
PremiumThe Fly
ImmunityBio falls -23.0%
17d ago
IBRX
ImmunityBio receives FDA warning letter on Anktiva promotion
PremiumThe Fly
ImmunityBio receives FDA warning letter on Anktiva promotion
17d ago
IBRX
ImmunityBio call volume above normal and directionally bullish
PremiumThe Fly
ImmunityBio call volume above normal and directionally bullish
18d ago
IBRX
ImmunityBio announces approval in Macau for Anktiva
PremiumThe Fly
ImmunityBio announces approval in Macau for Anktiva
21d ago
IBRX
Mixed options sentiment in ImmunityBio with shares up 3.53%
PremiumThe FlyMixed options sentiment in ImmunityBio with shares up 3.53%
23d ago
IBRX
Buy Rating on ANKTIVA: NCCN Guideline Expansion, Off‑Label Upside, and DCF‑Backed Risk‑Reward in BCG‑Unresponsive NMIBC
Premium
Ratings
Buy Rating on ANKTIVA: NCCN Guideline Expansion, Off‑Label Upside, and DCF‑Backed Risk‑Reward in BCG‑Unresponsive NMIBC
23d ago
IBRX
Expanding ANKTIVA’s NMIBC Opportunity: NCCN Endorsement, FDA Flexibility, and Strengthening Long‑Term Prospects for ImmunityBio
Premium
Ratings
Expanding ANKTIVA’s NMIBC Opportunity: NCCN Endorsement, FDA Flexibility, and Strengthening Long‑Term Prospects for ImmunityBio
24d ago
IBRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >